

Sae-Won Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8748728/publications.pdf>

Version: 2024-02-01

199
papers

6,552
citations

53794

45
h-index

82547

72
g-index

201
all docs

201
docs citations

201
times ranked

11082
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib. <i>Journal of Clinical Oncology</i> , 2005, 23, 2493-2501.	1.6	736
2	Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. <i>Clinical Cancer Research</i> , 2006, 12, 2538-2544.	7.0	245
3	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. <i>PLoS ONE</i> , 2017, 12, e0189848.	2.5	190
4	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. <i>PLoS ONE</i> , 2015, 10, e0139749.	2.5	183
5	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer. <i>International Journal of Cancer</i> , 2005, 113, 109-115.	5.1	152
6	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 115-124.	10.7	147
7	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2015, 17, 33.	5.0	138
8	RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 865-877.	4.1	116
9	High-purity capture and release of circulating exosomes using an exosome-specific dual-patterned immunofiltration (ExoDIF) device. <i>Nanoscale</i> , 2017, 9, 13495-13505.	5.6	116
10	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3502-3502.	1.6	114
11	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992.	7.0	107
12	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. <i>Cancer Letters</i> , 2013, 335, 145-152.	7.2	100
13	Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Clinical Cancer Research</i> , 2019, 25, 6141-6147.	7.0	98
14	RNA editing in <i>RHOQ</i> promotes invasion potential in colorectal cancer. <i>Journal of Experimental Medicine</i> , 2014, 211, 613-621.	8.5	97
15	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	1.8	93
16	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2015, 47, 607-615.	3.0	93
17	Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2. <i>PLoS ONE</i> , 2009, 4, e5933.	2.5	91
18	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. <i>Lung Cancer</i> , 2008, 61, 30-34.	2.0	89

#	ARTICLE	IF	CITATIONS
19	Epigenetic-Based Therapies in Cancer. <i>Drugs</i> , 2011, 71, 2391-2403.	10.9	88
20	Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02. <i>Journal of Clinical Oncology</i> , 2013, 31, 1732-1739.	1.6	78
21	Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing. <i>PLoS ONE</i> , 2013, 8, e64271.	2.5	71
22	Association Between <i>Fusobacterium nucleatum</i> , Pathway Mutation, and Patient Prognosis in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 3389-3395.	1.5	69
23	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2526-2536.	4.1	65
24	Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1045-1055.	2.3	64
25	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012, 106, 303-313.	2.9	64
26	Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016, 7, 58007-58021.	1.8	63
27	Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 439-451.	4.1	62
28	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2520-2529.	7.0	59
29	Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 593-599.	1.3	58
30	Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 16-26.	4.1	57
31	The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. <i>Cancer Research and Treatment</i> , 2016, 48, 171-179.	3.0	56
32	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 313-319.	1.5	54
33	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 320-325.	1.1	54
34	Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. <i>Cancer</i> , 2010, 116, 2890-2901.	4.1	53
35	Whole-Body Distribution and Radiation Dosimetry of ⁶⁸ Ga-NOTA-RGD, a Positron Emission Tomography Agent for Angiogenesis Imaging. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 65-71.	1.0	52
36	KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX. <i>Annals of Surgical Oncology</i> , 2015, 22, 187-194.	1.5	52

#	ARTICLE	IF	CITATIONS
37	Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. <i>Experimental and Molecular Medicine</i> , 2013, 45, e64-e64.	7.7	51
38	Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 254-262.	5.3	51
39	Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 607-615.	4.1	50
40	Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. <i>Cancer</i> , 2017, 123, 3513-3523.	4.1	50
41	Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. <i>Oncotarget</i> , 2017, 8, 2329-2341.	1.8	50
42	Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. <i>International Journal of Cancer</i> , 2013, 132, 2209-2216.	5.1	49
43	Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013, 45, 325-333.	3.0	49
44	Activation of WNT/catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. <i>International Journal of Cancer</i> , 2019, 144, 389-401.	5.1	48
45	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. <i>Cancer Letters</i> , 2011, 302, 155-165.	7.2	47
46	Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. <i>Cancer Science</i> , 2011, 102, 1388-1395.	3.9	46
47	The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 637-641.	2.5	46
48	Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 164-171.	6.4	43
49	RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. <i>Cancer Letters</i> , 2010, 299, 22-28.	7.2	42
50	Ataxia-telangiectasia mutated protein expression with microsatellite instability in gastric cancer as prognostic marker. <i>International Journal of Cancer</i> , 2014, 134, 72-80.	5.1	42
51	Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody. <i>PLoS ONE</i> , 2012, 7, e33322.	2.5	41
52	Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2015, 18, 16.	1.9	38
53	Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 843-851.	2.3	37
54	Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor Immune Microenvironment in Colorectal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 870-881.	7.0	37

#	ARTICLE	IF	CITATIONS
55	Diffusion-Related MRI Parameters for Assessing Early Treatment Response of Liver Metastases to Cytotoxic Therapy in Colorectal Cancer. <i>American Journal of Roentgenology</i> , 2016, 207, W26-W32.	2.2	36
56	Adjuvant Chemoradiotherapy After Curative Resection for Extrahepatic Bile Duct Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 136-140.	1.3	35
57	Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1323-1331.	2.3	34
58	Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers. <i>Laboratory Investigation</i> , 2012, 92, 1033-1044.	3.7	34
59	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1301-1308.	2.5	32
60	p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2019, 120, 797-805.	6.4	32
61	Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 94-100.	2.1	31
62	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 597-606.	5.3	31
63	Epidermal Growth Factor Receptor Mutations and Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 344-350.	1.3	29
64	Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: A retrospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1537-1542.	2.8	29
65	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 395-403.	2.2	28
66	Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. <i>Gastric Cancer</i> , 2013, 16, 581-589.	5.3	28
67	FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers <i>in vitro</i> . <i>Molecular Oncology</i> , 2018, 12, 993-1003.	4.6	28
68	The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. <i>Anticancer Research</i> , 2012, 32, 1547-53.	1.1	28
69	Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 757-764.	6.4	27
70	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	7.0	27
71	Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. <i>Oncotarget</i> , 2017, 8, 79441-79452.	1.8	26
72	Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal) <i>Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50</i>	1.3	25

#	ARTICLE	IF	CITATIONS
73	Polyester fabric sheet layers functionalized with graphene oxide for sensitive isolation of circulating tumor cells. <i>Biomaterials</i> , 2017, 125, 1-11.	11.4	25
74	Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. <i>Journal of Biological Chemistry</i> , 2020, 295, 1105-1119.	3.4	25
75	Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. <i>Cancer Science</i> , 2010, 101, 793-799.	3.9	24
76	Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e39943.	2.5	24
77	High serum TGF- β predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 107-114.	2.5	21
78	Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. <i>Anti-Cancer Drugs</i> , 2012, 23, 288-297.	1.4	21
79	Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: Preliminary results of a prospective study. <i>European Journal of Radiology</i> , 2012, 81, 3542-3550.	2.6	21
80	Dynamic cohesin-mediated chromatin architecture controls epithelial-mesenchymal plasticity in cancer. <i>EMBO Reports</i> , 2016, 17, 1343-1359.	4.5	21
81	A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 777-785.	2.3	21
82	Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0145004.	2.5	20
83	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 28-36.	3.0	20
84	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. <i>BMC Cancer</i> , 2015, 15, 721.	2.6	19
85	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016, 115, 1201-1205.	6.4	19
86	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017, 49, 1033-1043.	3.0	19
87	Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. <i>PLoS ONE</i> , 2020, 15, e0232754.	2.5	19
88	Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 1404-1412.	2.6	18
89	HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 109-115.	2.3	18
90	Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability. <i>Nucleic Acids Research</i> , 2016, 44, 558-572.	14.5	18

#	ARTICLE	IF	CITATIONS
91	Epithelial and mesenchymal circulating tumor cell isolation and discrimination using dual-immunopatterned device with newly-developed anti-63B6 and anti-EpCAM. <i>Sensors and Actuators B: Chemical</i> , 2018, 260, 320-330.	7.8	18
92	The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 13-25.	1.2	17
93	Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. <i>Clinical Epigenetics</i> , 2015, 7, 63.	4.1	17
94	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). <i>Breast Cancer Research and Treatment</i> , 2015, 152, 77-85.	2.5	17
95	The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study. <i>Cancer Research and Treatment</i> , 2018, 50, 1186-1193.	3.0	17
96	Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer. <i>Molecular Oncology</i> , 2022, 16, 2396-2412.	4.6	17
97	The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. <i>Investigational New Drugs</i> , 2012, 30, 2148-2160.	2.6	15
98	Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data. <i>Journal of Breast Cancer</i> , 2012, 15, 427.	1.9	15
99	Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1435-1443.	2.3	15
100	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. <i>Oncologist</i> , 2015, 20, 926-933.	3.7	15
101	Enhancement of isolation sensitivity for the viable heterogeneous circulating tumor cells swelled by hypo-osmotic pressure. <i>RSC Advances</i> , 2017, 7, 49684-49693.	3.6	15
102	Incidence and Risk of Oxaliplatin-Induced Hypersensitivity in Patients with Asymptomatic Prior Exposure: A Prospective Observational Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1642-1648.e2.	3.8	15
103	Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 98-107.e1.	2.4	15
104	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. <i>PLoS ONE</i> , 2016, 11, e0151406.	2.5	15
105	Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. <i>Cancer Research and Treatment</i> , 2016, 48, 990-997.	3.0	15
106	Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 391-395.	2.4	14
107	Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1021-1029.	2.3	14
108	Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients. <i>Clinical Epigenetics</i> , 2016, 8, 36.	4.1	14

#	ARTICLE	IF	CITATIONS
109	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 230-236.	6.4	14
110	Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. <i>Scientific Reports</i> , 2021, 11, 16333.	3.3	14
111	More Accurate Prediction of Metastatic Pancreatic Cancer Patients'™ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. <i>PLoS ONE</i> , 2016, 11, e0145692.	2.5	14
112	Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1133-1140.	2.5	13
113	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 164-174.	5.3	13
114	Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. <i>Journal of Breast Cancer</i> , 2017, 20, 347.	1.9	13
115	CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. <i>World Journal of Gastroenterology</i> , 2013, 19, 1438.	3.3	13
116	NFATC3-PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines. <i>Cancer Research and Treatment</i> , 2019, 51, 391-401.	3.0	13
117	Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment. <i>British Journal of Cancer</i> , 2022, 127, 898-907.	6.4	13
118	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 821-836.	3.1	12
119	Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. <i>Cancer Letters</i> , 2012, 321, 128-136.	7.2	12
120	Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 2242-2249.	1.5	12
121	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102.	4.9	12
122	Central Pontine Myelinolysis in a Patient with Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation: A Case Report. <i>Journal of Korean Medical Science</i> , 2008, 23, 324.	2.5	11
123	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016, 16, 515.	2.6	11
124	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016, 19, 421-430.	5.3	11
125	Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 147-153.	1.0	11
126	Src as a Therapeutic Target in Biliary Tract Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1515-1524.	4.1	10

#	ARTICLE	IF	CITATIONS
127	Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 233-241.	2.5	10
128	Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells. <i>Molecular Oncology</i> , 2018, 12, 1398-1409.	4.6	10
129	Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial. <i>Scientific Reports</i> , 2020, 10, 19467.	3.3	10
130	Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX. <i>Scientific Reports</i> , 2021, 11, 14609.	3.3	10
131	Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 125-129.	1.3	10
132	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1045-1055.	3.0	10
133	Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. <i>BMC Cancer</i> , 2015, 15, 690.	2.6	9
134	Novel graded prognostic assessment for colorectal cancer patients with brain metastases. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1112-1120.	2.2	9
135	Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 453-460.	2.5	9
136	Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Cancer Research and Treatment</i> , 2017, 49, 1153-1163.	3.0	9
137	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 1096-1103.	3.0	9
138	Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. <i>Cancer Letters</i> , 2012, 316, 77-84.	7.2	8
139	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 707-714.	2.5	8
140	Prognostic effects of abnormal DNA damage response protein expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 117-127.	2.5	8
141	Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 165-175.	2.3	7
142	A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 252.	2.6	7
143	Viable and high-throughput isolation of heterogeneous circulating tumor cells using tapered-slit filters. <i>Sensors and Actuators B: Chemical</i> , 2020, 321, 128369.	7.8	7
144	Circulating Tumor Marker Isolation with the Chemically Stable and Instantly Degradable (CSID) Hydrogel ImmunoSpheres. <i>Analytical Chemistry</i> , 2021, 93, 1100-1109.	6.5	7

#	ARTICLE	IF	CITATIONS
145	Postoperative chemoradiotherapy in high risk locally advanced gastric cancer. <i>Radiation Oncology Journal</i> , 2012, 30, 213.	1.5	7
146	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. <i>Anticancer Research</i> , 2014, 34, 4275-80.	1.1	7
147	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1017-1026.	2.3	6
148	Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System. <i>Materials</i> , 2015, 8, 519-534.	2.9	6
149	Identification of Long-Range Epigenetic Silencing on Chromosome 15q25 and Its Clinical Implication in Gastric Cancer. <i>American Journal of Pathology</i> , 2015, 185, 666-678.	3.8	6
150	The Prognostic Importance of the Number of Metastatic Lymph Nodes for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiotherapy for Extrahepatic Bile Duct Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1833-1841.	1.7	6
151	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3076-3076.	1.6	6
152	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 3376-88.	1.4	6
153	Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07. <i>Journal of Clinical Oncology</i> , 2022, 40, 3868-3877.	1.6	6
154	Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 346-349.	1.3	5
155	Ki-67 level in hormone receptor positive breast cancer patients: A retrospective review of 9,061 Korean women.. <i>Journal of Clinical Oncology</i> , 2013, 31, 551-551.	1.6	5
156	Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma. <i>Anticancer Research</i> , 2010, 30, 5245-50.	1.1	5
157	VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 143-147.	2.1	4
158	Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors. <i>Journal of Breast Cancer</i> , 2013, 16, 66.	1.9	4
159	Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 447-455.	2.3	4
160	A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2019, 24, 1037-e636.	3.7	4
161	A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	4
162	A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 681-681.	1.6	4

#	ARTICLE	IF	CITATIONS
163	Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1023-1029.	2.3	3
164	Results of re-irradiation for pelvic recurrence in anorectal cancer patients. <i>British Journal of Radiology</i> , 2019, 92, 20180794.	2.2	3
165	Phenotype-based single cell sequencing identifies diverse genetic subclones in CD133 positive cancer stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 558, 209-215.	2.1	3
166	The impact of diabetes mellitus and metformin on survival of patients with advanced pancreatic cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4044-4044.	1.6	3
167	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3576-3576.	1.6	3
168	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 561-568.	2.6	2
169	Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. <i>BMC Cancer</i> , 2019, 19, 421.	2.6	2
170	A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1003-1003.	1.6	2
171	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in previously treated advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 269-269.	1.6	2
172	378â€¦A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. , 2020, , .		2
173	Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery. <i>Anticancer Research</i> , 2014, 34, 6685-90.	1.1	2
174	Prognostic Impact of Extramural Lymphatic, Vascular, and Perineural Invasion in Stage II Colon Cancer: A Comparison With Intramural Invasion. <i>Diseases of the Colon and Rectum</i> , 2022, Publish Ahead of Print, .	1.3	2
175	Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptorâ€“Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea. <i>Cancer Research and Treatment</i> , 2023, 55, 334-343.	3.0	2
176	The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV Breast Cancer. <i>Journal of Breast Cancer</i> , 2010, 13, 90.	1.9	1
177	Angiogenesis Imaging Using 68Ga-RGD PET: Preliminary Report from Seoul National University Hospital. <i>Current Medical Imaging</i> , 2010, 6, 56-59.	0.8	1
178	A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1175-1182.	2.3	1
179	Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 158-162.	1.3	1
180	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2021, 39, 1335-1347.	2.6	1

#	ARTICLE	IF	CITATIONS
181	Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2565-2565.	1.6	1
182	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 492-492.	1.6	1
183	Comparison of concurrent chemoradiotherapy and chemotherapy alone for locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 351-351.	1.6	1
184	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. Cancer Research and Treatment, 2017, 49, 454-463.	3.0	1
185	Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. Journal of Clinical Oncology, 2017, 35, 416-416.	1.6	1
186	Longitudinal monitoring of circulating tumor DNA (ctDNA) during disease course of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 189-189.	1.6	1
187	Role of Dedicated Subspecialized Radiologists in Multidisciplinary Team Discussions on Lower Gastrointestinal Tract Cancers. Korean Journal of Radiology, 2022, 23, .	3.4	1
188	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. Nutrition and Cancer, 2016, 68, 750-755.	2.0	0
189	Genetic polymorphisms and ethnic difference in outcome of adjuvant FOLFOX chemotherapy in Korean patients with colon cancer.. Journal of Clinical Oncology, 2012, 30, 623-623.	1.6	0
190	Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 3624-3624.	1.6	0
191	Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer.. Journal of Clinical Oncology, 2013, 31, 182-182.	1.6	0
192	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy.. Journal of Clinical Oncology, 2013, 31, e15066-e15066.	1.6	0
193	TTP or PFS as a surrogate endpoint in advanced hepatocellular carcinoma treated with systemic therapy.. Journal of Clinical Oncology, 2016, 34, 4075-4075.	1.6	0
194	Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer.. Journal of Clinical Oncology, 2016, 34, e23268-e23268.	1.6	0
195	Korean Cancer Patients's Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. Journal of Clinical Oncology, 2016, 34, 10067-10067.	1.6	0
196	Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. Journal of Clinical Oncology, 2017, 35, 460-460.	1.6	0
197	Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials.. Journal of Clinical Oncology, 2017, 35, 454-454.	1.6	0
198	Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapelRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.. Journal of Clinical Oncology, 2019, 37, 711-711.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	2.5	0